2023 Poster Presentations Coming in July
2022 Poster Presentations
P01: Construction of CBET’s Pipeline for Recombinant GFP Production and Purification, Presented by Nicholas L., Albany College of Pharmacy
P02: Assessment of Sartorius Gen 2 Bags as Alternative Containers for mAb Drug Substances, Presented by Dmitry G., Amgen, Inc.
P03: A Novel Cell Lysis Method to Improve Viral Vector Manufacturing Process, Presented by Jungmin O., Avantor, Inc.
P04: Interfacial Properties of BASF Surfactants for the Stabilization of Antibody Formulations, Presented by Philip B., BASF Corporation
P05: Leveraging High-Throughput Ambr15 and Ambr250 Technologies to Advance Upstream Gene Therapy Process Development, Presented by Maria C-A., Biogen
P06: Lipid Nanoparticles for Site-Specific Drug Delivery: A Versatile Platform for Modeling Endothelial Dysfunction in Zebrafish, Presented by Justine W., Boston Medical Center
P07: Upstream Clarification Strategies for Increased Filtration Throughput and Ease of Manufacturing, Presented by Taylor M., BridgeBio
P08: Overcoming Supply Chain Challenges for Various Filters Used in Commercial Biologics Downstream Manufacturing, Presented by Kalyn L., Bristol Myers Squibb
P09: Implementing Multi-Column Chromatography for Batch Mode Commercial Product, Presented by Yuanpu W., Bristol Myers Squibb
P10: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures, Presented by Larry F., CHO Plus, Inc.
P11: Analytical Tools for Characterization and Rapid Quantification of Extracellular Vesicles from Cell Culture Supernatant, Presented by Anjali C., Codiak BioSciences
P12: Streamlined Industrial Formulation Affords Long-Term Storage Stability of Extracellular Vesicles, Presented by Lisa J., Codiak BioSciences
P13: Corning® Ascent™ Fixed Bed Reactor (FBR), an Automated, Scalable and Closed System for High Efficiency Cell and Gene Therapy Manufacturing, Presented by Chris S., Corning Research and Development Corporation
P14: Accelerating Antibody Research and Discovery Through Gator® BLI Biosensor Technology, Presented by Chip S., Gator Bio
P15: The Development of High-Concentration Fc-GLA for Fabry Disease Treatment, Presented by Miroo K., GC Biopharma
P16: Increasing Throughput and Sensitivity While Reducing False-Positives in Host Cell Protein (HCP) Analysis, Presented by Amy C., Genedata Ltd.
P17: To Mix Effectively and Not Kill: Fluid Dynamics and Energy Dissipation Rate Distribution in AppliFlex Bioreactors, Presented by George B., Getinge Applikon
P18: High-Throughput, Automated Analysis of Viral Vector Titer and Process-Related Impurities Accelerates Downstream Process Development, Presented by Ellen L., Gyros Protein Technologies
P19: Aura+: High Throughput, Low Volume Product Stability and Purity Analysis for Gene and Cell Therapies, Presented by Karessa W., Halo Labs
P20: Complete mAb Stability Characterization: From CHO Cell Line Development to Degraded Polysorbate ID, Presented by Karessa W., Halo Labs
P21: A Novel Surfactant Compatible with Protein Bioprocessing, Presented by Hadi F., IFF Pharma Solutions
P22: Microglassification™: A Novel and Rapid Dehydration Technology, Presented by Adam R., Lindy Biosciences, Inc.
P23: Microglassification™ Technology to Streamline Drug Substance Processing and Preservation, Presented by Samantha S., Lindy Biosciences, Inc.
P24: Microglassification™ to Make High Concentration Protein Particle Suspensions for Subcutaneous Injections, Presented by Samantha S., Lindy Biosciences, Inc.
P25: Establishing Procedure for Lab Scale Verification of Thermal Inactivation of BSL-2 Organism in Commercial Vaccine Manufacturing Facility, Presented by Michelle I., Merck & Co., Inc.
P26: Saccharomyces cerevisiae Fed-Batch Fermentation Scale-Down Case Study: A Practical Approach to Establish AMBR250 Model from Manufacturing-Relevant Process, Presented by Zhiguo L., Merck & Co., Inc.
P27: Investigation into the Use of Gamma Irradiated Cytodex-1 Microcarriers to Produce a Human Cytomegalovirus (HCMV) Vaccine Candidate in Epithelial Cells, Presented by Daniel S., Merck & Co., Inc.
P28: ambr250 HT System: A Key Bioreactor Process Development Tool for Industrial Vaccine and Oncolytic Virus Production, Presented by Marena T., Merck & Co., Inc.
P29: Scale-Up and Downstream Optimization of a Novel Dengue Live Virus Vaccine, Presented by Christopher W., Merck & Co., Inc.
P30: De-Novo Assembly and Annotation of the CHOZN GS-/- Genome Supports High-Throughput Genome-Scale Screening, Presented by David R., MilliporeSigma
P31: Impact of Trace Metal Impurities on Media and Feed Performance, Presented by Ryan S., MilliporeSigma
P32: Raman Spectroscopy for Use in Cell Culture Media Characterization, Presented by Henry T., MilliporeSigma
P33: Microfluidic Hanging Drops for Cell Spheroids Culture, Presented by Chia-Hsien H., National Health Research Institute, Institutes of Biomedical Engineering and Nanomedicine
P34: Pragmatic Control Concepts for End-to-End Drug Substance Continuous Manufacturing Platform, Presented by Thomas E., National Resilience
P35: Evaluation of Optimal Conditions for the Reduction of Host Cell and Plasmid DNA, Presented by Supriya K., Passage Bio
P36: Preliminary Evaluation of PendoTECH® Single Use Sensors Post X-Ray Irradiation, Presented by Nick T., PendoTECH
P37: Analytical Assessment of AAV Capsid at Harvest, Presented by Yulia I., Pfizer, Inc.
P38: Impact of Aeration Strategies in Benchtop CHO Cell Fed-Batch Bioreactors for SARS-CoV-2 Spike Protein Production, Presented by Lucas L., Polytechnique Montreal
P39: Transfer-Rate Online Measurement (TOM) System for Analyzing the Respiratory Activity of a Chinese Hamster Ovary (CHO) Cell Pool Expressing SARS-CoV-2 Spike Protein in a Fed-Batch Process, Presented by Juan Sebastian RD., Polytechnique Montreal
P40: A Simple, Rapid Method for Baculovirus Titer Determination and Detection of Residual Baculoviral DNA by Digital Droplet PCR, Presented by Mary N., Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly
P41: Characterization of Maurice™ CE-SDS PLUS for USP <129> Suitability, Presented by Yasef K., ProteinSimple, a Bio-Techne Brand
P42: Lentiviral Vector Analysis for Cell and Gene Therapy Made Easy, Presented by Rachel T., ProteinSimple, a Bio-Techne Brand
P43: AVIPure CH1: A High Capacity, NaOH Tolerant Affinity Chromatography Resin for Purification of Antibody-Derived Therapeutics, Presented by Thomas S., Repligen
P44: Gotta Catch 'Em All: Plasmid DNA Purification Development for In Vivo Gene Therapy, Presented by Sabrina K., Roche Diagnostics GmbH
P45: Developing Scale Down High Throughput Cultivation System and Spent Media Analysis Platform for CHO Cell Culture Media Development and Optimization, Presented by Jason M., Sartorius Stedim North America, Inc.
P46: Speed Up Your AAV Vector Development and Manufacturing with HEK293 Suspension-Based Platforms, Presented by Jason M., Sartorius Stedim North America, Inc.
P47: Scientific Solutions for Regulatory Guidelines: Unlocking AAV Product Testing, Presented by Catriona T., Sartorius Stedim North America, Inc.
P48: Pioneering the Details: A Multi-Method Collaboration to Gain Insight Into Structure and Thermal Stability of Lipid Nanoparticles (LNPs) for mRNA Delivery, Presented by Sven Even B., SINTEF
P49: Automated Large-Scale T Cell Isolation in a New Closed Cell Separation System, Presented by Vesna P., STEMCELL Technologies
P50: Optimization of HEK Platform to Improve Viral Titer Production, Presented by Jackson L., Tenaya Therapeutics
P51: Enhanced Single-Use Fermentor (eS.U.F.) for Improved Cooling and Oxygen Mass Transfer, Presented by Josh A., Thermo Fisher Scientific
P52: A qPCR Based Assay to Quantitate Sf-Rhabdovirus for GMP Lot Release in Gene Therapy and Vaccine Manufacturing, Presented by Darren B., Thermo Fisher Scientific
P53: Validation and Approval for Lot-Release Testing of a Rapid Mycoplasma Assay, Presented by Darren B., Thermo Fisher Scientific
P54: A Multiplex qPCR Based System to Quantitate Residual Plasmids with Kanamycin Resistance Genes for GMP Lot Release in Gene Therapy and Vaccine Manufacturing, Presented by Jonas B., Thermo Fisher Scientific
P55: resDNASEQ™ HEK293 and E1A Fragment Length Quantitative Assays: Comprehensive Solution for GMP Lot Release in Gene Therapy and Vaccine Manufacturing, Presented by Jonas B., Thermo Fisher Scientific
P56: Scalability of the AAV-MAX Helper-Free AAV Production System for Adeno- Associated Virus (AAV) Production, Presented by Jacqueline H., Thermo Fisher Scientific
P57: Assessing Key Attributes of Adeno-Associated Viral Proteins Using UHPLC-FLD-Intact Accurate Mass Analysis, Presented by Reiko K., Thermo Fisher Scientific
P58: Scale-Up from a Benchtop Bioreactor to a 5,000 L Single-Use Bioreactor Using a mAb-Producing CHO Clone, Presented by Jace P., Thermo Fisher Scientific
P59: AAV-MAX System: Downstream Process and Scalability, Presented by Nils W., Thermo Fisher Scientific
P60: Characterization of mRNA Vaccine 5' and 3' End Products Using BioPharma Finder 5.0, Presented by Yi Z., Thermo Fisher Scientific
P61: Next Generation Downstream Process Development of a Recombinant Adeno-Associated Virus Treating Glycogen Storage Disease Ia, Presented by Wenjun D., Ultragenyx Pharmaceutical, Inc.
P62: Adaptation of an Automated ELISA Platform for Impurity Quantifications, Presented by Will S., Ultragenyx Pharmaceutical, Inc.
P63: Improved Host Cell Protein Reduction through Harvest Tangential Flow Filtration in rAAV Purification Process, Presented by Hanson Z., Ultragenyx Pharmaceutical, Inc.
P64: Process Development for Extracellular Vesicle Purification Using Affinity Chromatography, Presented by Benjamin B., University College London
P65: Assessing the Immunogenic Potential of CHO Host Cell Proteins by Combining Native Fractionation, LC-MS and In Vitro Cell Assay, Presented by Sherin P., University of Applied Sciences Northwestern Switzerland
P66: Antigen-Adjuvant Interactions, Stability, and Immunogenicity Profiles of a SARS-CoV-2 Receptor-Binding Domain (RBD) Antigen Formulated with Aluminum Salt and CpG Adjuvants, Presented by Sakshi B., University of Kansas, Lawrence
P67: Multi-Dose Vaccine Formulation Development with HPV VLPs, Presented by Nitya S., University of Kansas, Lawrence
P68: Optimizing Tangential Flow Filtration (TFF) Using Hollow Fiber for AAV Formulation, Presented by Xiaolong L., University of Pennsylvania
P69: DNA-Methylation and Personalized Medicine: A Challenge in Bioprocessing, Presented by Dolores C., University of Valencia, CIBEROBN
P70: Process Improvements for AAV Production by Transient Transfection of HEK293 Cells, Presented by Stephanie D., Vertex Pharmaceuticals
P71: Rapid Cycling using the GORE® Protein Capture Device with Protein A, 58 mL for Clinical Applications, Presented by Jeff C., W. L. Gore & Associates, Inc.
P72: Immunogenicity and Protection Efficacy of a Novel mRNA Based SARS-CoV2 Vaccine Candidate, Presented by Hyun P., Wonkwang University
P73: Automated Bioreactor System for Patient-Specific Immune Cell Manufacturing: From Process Development to Clinical-Scale Manufacturing, Presented by Dan L., A*STAR, Bioprocessing Technology Institute
P74: Lyophilization Process Development of a Freezing Stress Sensitive Bispecific Antibody, Presented by Hanmin D., AbbVie
P75: Using Digital Twin Facility Models to Predict Optimization Targets for Process Intensification, Presented by Andreas A., Boehringer Ingelheim Pharma GmbH & Co. KG
P76: Fast Screening of Peptide Drug Candidates Through SEC-HDX-MS/MALDI-HDX-MS and Circular Dichroism to Facilitate Peptide Lead Optimization, Presented by Yuan J., Merck & Co., Inc.
P77: Evaluation of Viscosity Reducing Excipients in the Development of High Concentration Monoclonal Antibody (mAb) Formulations, Presented by Prachi J., Teva Branded Pharmaceutical Products R&D, Inc.
P78: Understanding the Impact of Media and Amino Acid Concentrations on Antibody Product Quality Glycan Profiles, Presented by David P., U.S. Food and Drug Administration
P79: Rapid and High-Throughput IgG Quantification in Cell Culture Supernatant, Presented by Brian M., Valitacell Ltd.
P80: ChemStress® CHO Technology for Clone Robustness Ranking and Selection in Cell Line Development, Presented by Alessandra P., Valitacell Ltd.
P81: Process Characterization of Affinity Chromatography Step in Recombinant Adeno-Associated Virus Purification Process, Presented by Giuliana B., Ultragenyx Pharmaceutical, Inc.
P82: Predicting Viral Clearance Through CHO-RVLP and MVM-Mock Viral Particles: Characterization, Analysis and Utility in Downstream Process Development Activities, Presented by David C., Cygnus Technologies